Why Token Holders Are Not Shareholders

Crypto tokens look like stock. They are not. Here's the legal and economic gap every investor should understand before buying one.

10 min read
Intermediate
Published April 2026
The core idea

When you buy equity in a company, you own a piece of the business. You have a legal claim on profits, enforceable rights in a court, and seniority in a bankruptcy. When you buy a protocol's governance token, you own none of that. You own a speech-act, a voting chip, and a speculative bet that the team will decide, at some future date, to route real economic value to your address. Nothing compels them to do so.

Every Crypto Project Is Actually Two Entities

Almost every serious crypto protocol has a dual structure that most retail buyers do not understand:

  1. The Labs entity. This is a normal, for-profit company. It has a legal name (Uniswap Labs Inc., Aave Companies UK Ltd., and so on). It has employees, bank accounts, investors, and a cap table. It owns the IP, the brand, and frequently the front-end that users interact with. When VCs invest in a crypto project, they are almost always investing in the Labs entity, in exchange for equity, the same instrument you would get investing in any other startup.
  2. The DAO and the token. This is a separate, usually unincorporated, structure that nominally "governs" the protocol. The governance token is what gets distributed to the public. It is purposefully structured to not be equity, because if it were equity, it would be a security, and distributing it publicly without registration would be illegal in most jurisdictions.

The token and the equity are two different instruments with two different sets of rights. Labs investors get equity and all its legal protections. Token holders get a governance token and whatever rights are (or are not) written into the protocol's smart contracts.

The alignment problem
Because the Labs entity captures equity value and the token holders capture token value, there is a structural disconnect. The protocol can generate hundreds of millions in fees, flow them into the Labs company or a treasury controlled by Labs, and the token price can still collapse. The Labs team is not legally required to ever route a dollar of that revenue back to token holders. Whether they do is a choice, not an obligation.

Shareholders vs. Token Holders, Side by Side

Here is the comparison that most retail buyers never see explicitly:

Right Shareholder (Equity) Governance Token Holder
Legal claim on profits Yes, via dividends and retained earnings. Enforceable in court. None. No legal claim on any revenue or profit the protocol generates.
Claim on assets in bankruptcy Yes, last in line but a real claim against real assets. None. If the Labs entity fails, token holders have no standing as creditors.
Voting rights Enforceable corporate governance, audited board elections, fiduciary duty owed to shareholders. On-chain governance votes. No fiduciary duty owed to holders. Voter turnout is usually under 5%, and founding teams frequently hold enough tokens to decide any vote.
Right to sue for breach of duty Yes. Derivative suits, class actions, SEC enforcement. Effectively none. There is no recognized fiduciary relationship between the Labs team and token holders.
Audited financial statements Required by law for public companies. Not required. On-chain data gives partial visibility, but off-chain Labs revenue is usually opaque.
Dilution protection Preemptive rights, anti-dilution clauses, disclosed share issuance. Emissions schedules and treasury unlocks happen on-chain, but can often be changed by governance. Holders have no veto.
Value accrual mechanism Built into the security. Profits flow to equity by default. Must be explicitly engineered via buybacks, burns, or fee distributions. Many tokens have no such mechanism.

Read that table once more. The only column where token holders are not at a structural disadvantage is the last one, and even there the mechanism is optional. A token can exist for years with no value accrual mechanism at all, and its holders have no recourse.

Why This Actually Matters to Your Portfolio

The legal gap is not academic. It has direct, practical consequences for how you should evaluate a token before buying it.

1. "The protocol is growing" is not a thesis.

In traditional equity analysis, if a company's revenue grows, its fair equity value grows, because equity has a legal claim on that revenue. In crypto, protocol revenue can grow while the token does nothing, because the token has no claim on that revenue. The first question is always: Does the token have a mechanism to capture protocol value, and is that mechanism actually being used?

A common trap

A protocol announces record revenue. Twitter calls it bullish. The token does not move, or drifts lower. This is not a market "inefficiency." It is the market correctly pricing that the revenue is flowing to the Labs entity and not to the token holders. The information is already in the price. Your edge is understanding the legal structure, not the revenue number.

2. Governance rights are not enough.

"But the token has governance rights!" is a real argument you will see on Crypto Twitter. In practice, most governance tokens give holders the right to vote on proposals that the Labs team has pre-approved, in a process where the Labs team controls enough supply to decide any contested vote. This is ceremonial, not substantive. Voting without economic rights is theater.

3. The value accrual mechanism is the thing to evaluate.

Because value accrual is not automatic, the actual engineering of the mechanism is the most important thing to look at:

  • Buybacks: Does the protocol use its revenue to buy back tokens from the open market? How much? Is it automatic or discretionary? Can governance turn it off?
  • Burns: Does a portion of protocol fees permanently destroy tokens, reducing supply?
  • Direct fee distribution: Does the protocol route fees directly to stakers or to specific token addresses? What fraction of total revenue?
  • Supply discipline: Are emissions fixed or discretionary? Is the treasury allocation being dumped?

A protocol with an automatic, programmatic, meaningful value-accrual mechanism behaves much more like equity. A protocol without one behaves like a gift card you cannot redeem.

4. Holder revenue is the one number to memorize.

Across the entire crypto industry, only about 50 protocols returned more than $100,000 to token holders in the last 30 days. That is less than 1% of the tokens on CoinGecko. Most "tokens" are governance chips with no cash-flow claim, not investments. See The 1% Rule: Why Most Crypto Tokens Are Uninvestable for the full funnel.

When Tokens Actually Behave Like Equity

Not every token is hopeless. A small set of protocols have deliberately engineered their tokenomics to mimic equity-like economics, even without the legal rights. These are the ones worth taking seriously:

What "equity-like" actually looks like
  • Programmatic buybacks funded by real, external revenue (not token emissions). Hyperliquid's protocol fees funding HYPE buybacks is a current example.
  • Burn mechanics that meaningfully reduce supply relative to emission schedules.
  • Fee switches that route protocol revenue directly to stakers, without requiring a governance vote every quarter.
  • Hard-capped supply with a fully disclosed, non-discretionary emissions schedule.
  • Transparent treasury management, with on-chain visibility into how reserves are deployed.

Even here, there is no legal claim. The Labs team could change the buyback program tomorrow. But at least the current mechanics are real, measurable, and produce observable cash flow to holders. That is a defensible reason to own the token. "The protocol might decide to distribute value someday" is not.

A Simple Checklist Before Buying Any Token

Before you buy a governance token, answer these questions out loud. If you cannot, you are not investing, you are speculating:

  1. Who owns the equity in the Labs entity? Is the founder still in control?
  2. What exactly does the token entitle me to, in the smart contract?
  3. Is there a fee switch, buyback, or burn that is currently active and routes real revenue to holders?
  4. How much holder revenue did this protocol generate in the last 30 days? (If you cannot find this number, that is your answer.)
  5. What is the token's fully diluted valuation divided by its annualized holder revenue? Is it below 20x?
  6. What fraction of supply unlocks in the next 12 months, and who holds the unlocks?
  7. Is the value-accrual mechanism controlled by governance? Can the team turn it off?
  8. If the protocol succeeds wildly, does the token price actually benefit, or does all the upside flow to the Labs equity?
The TokenIntel view

Every asset on TokenIntel is evaluated with this legal-vs-economic gap in mind. The signals, the fundamental scores, and the thesis framework all prioritize tokens with real, programmatic value-accrual mechanisms over tokens that are pure governance chips. You will not find us covering 17,000 tokens. You will find us covering the few where the legal gap has been engineered around, credibly.

Further Reading